"In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002;Actividad "in vitro" de 10 antimicrobianos frente a bacterias anaerobias. Estudio multicéntrico, 1999-2002

Revista Argentina de Microbiologia

Volumn 36, Issue 3, 2004, Pages 130-135

  Litterio, M ^a   Bianchini, H ^a   Carloni, G ^a   Di Martino, A ^b   Fernandez Canigia L ^c   Greco, G ^d   Legaria, C ^e   Rollet, R ^f   Rossetti, A ^g   Predari, S C ^h   Castello, L ^h  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Sanatorio Mitre   (Argentina)

^c HOSPITAL ALEMÁN   (Argentina)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e Hospital de Agudos Enrique Tomu   (Argentina)

^f HOSPITAL F J MUÑIZ   (Argentina)

^g HIGA Pte Peron Avellaneda   (Argentina)

^h INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

Author keywords

Anaerobic bacteria; Resistance; Susceptibility

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CEFTRIAXONE; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

AGAR GEL DIFFUSION; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARGENTINA; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; FUSOBACTERIUM; FUSOBACTERIUM NUCLEATUM; GRAM POSITIVE COCCI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS; PREVOTELLA;

ANTI-BACTERIAL AGENTS; ARGENTINA; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE ANAEROBIC BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

EID: 8344278752     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. B) resistance to moxifloxacin in Clostridium difficile. J. Antimicrob. Chemother. 51: 599-603.
2. Aldridge K, Ashcraft D, Cambre K, Pierson C, Jenkins S, Rosenblatt J (2001) Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 45: 1238-1243.
3. Aldridge K, Ashcraft D, O'Brien M, Sanders Ch (2003) Bacteremia due to Bacteroides fragilis group: distribution of species, b-lactamase production, and antimicrobial susceptibility patterns. Antimicrob. Agents Chemother. 47: 148-153.
4. Bianchini H, Berenstein P, Notario R, Litterio M, Greco G, Hardie N, et al (1994) Estudio multicéntrico de la sensibilidad de bacterias anaerobias en la Argentina. Infect. y Microbiol. Clín. 6: 7-19.
5. Bianchini H, Fernández Cangia L, Bantar C, Smayevsky J (1997) Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20 year study at a medical center in Buenos Aires, Argentina. Clin. Infect. Dis. 25 (Suppl 2): 268-269.
6. Citron D, Appleman M (2001) Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria. Antimicrob. Agents Chemother. 45: 345-348.
7. Citron D, Merrian C, Tyrrell K, Warren Y, Fernandez H, Goldstein E (2003) In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob. Agents Chemother. 47: 2334-2338.
8. Ednie L, Jacobs M, Appelbaum P (1997) Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). Antimicrob. Agents Chemother. 41: 2019-2022.
9. Finegold S (1995). Anaerobic infections in humans: an overview. Anaerobe 1: 3-9.
10. Finegold SM (1995) Anaerobic bacteria: general concepts. En: Mandell GL , Bennett JE, Dolin R (Ed), Principles and practice of infectious diseases, Churchill Livingstone Inc. USA, p. 2156-2173.
11. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H (2003) In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob. Agents Chemother. 47: 337-341.
12. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H (2003) In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 47: 1963-1967.
13. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H (2002) Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J. Antimicrob. Chemother. 50: 411-420.
14. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H (2003) In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 47: 3008-3011.
15. Hoellman D, Kelly L, Jacobs M, Appelbaum P (2001) Comparative antianaerobic activity of BMS 284756. Antimicrob. Agents Chemother. 45: 589-592.
16. Kleinkauf N, Ackermann G, Schaumann R, Rodloff A (2001) Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob. Agents Chemother. 45: 1896-1899.
17. Litterio M, Castello L, Rollet R, Di Martino A, Greco G, Fernández Canigia L, et al (1999) Susceptibility of anaerobic gram-negative rods to trovafloxacin and other eight antibiotics. A collaborative study from Argentina. Drugs 58 (Suppl 2): 193-194.
18. Milazzo I, Blandino G, Caccamo F, Musumeci R, Nicoletti G, Speciale A (2003) Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. J. Antimicrob. Chemother. 51: 721-725.
19. National Committee for Clinical Laboratory Standards (2001) Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard- Fifth edition. NCCLS document M11-A5, Wayne, PA, USA.
20. National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing; Twelfth Informational Supplement. NCCLS document M100-S12, Wayne, PA, USA.
21. Nyfors S, Könönen E, Syrjänen R, Komulainen E, Jousimies-Somer H (2003) Emergence of penicillin resistance among Fusobacterium nucleatum populations of commensal oral flora during early childhood. J. Antimicrob. Chemother. 51: 107-112.
22. Nyfors S, Könönen E, Takala A, Jousimies-Somer H (1999) b-lactamase production by oral anaerobic gram-negative species in infants in relation to previous antimicrobial therapy. Antimicrob. Agents Chemother. 43: 1591-1594.
23. Peláez T, Alcalá L, Alonso R, Rodríguez- Créixems M, García-Lechuz J, Bouza E (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46: 1647-1650.
24. Snydman D, Jacobus N, McDermott L, Ruthazer R, Goldstein E, Finegold S et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob. Agents Chemother. 46: 3276-3279.
25. th ed. Star Publishing Company, Belmont, CA.
26. Wexler H, Molitoris D, St. John S, Vu A, Read E, Finegold S (2002) In vitro activities of faropenem against 579 strains of anaerobic bacteria. Antimicrob. Agents Chemother. 46: 3669-3675.